Literature DB >> 32393635

The PDK1-FoxO1 signaling in adipocytes controls systemic insulin sensitivity through the 5-lipoxygenase-leukotriene B4 axis.

Tetsuya Hosooka1, Yusei Hosokawa1, Kaku Matsugi1, Masakazu Shinohara2,3, Yoko Senga1, Yoshikazu Tamori1,4, Chikako Aoki1, Sho Matsui5, Tsutomu Sasaki5, Tadahiro Kitamura5, Masashi Kuroda6, Hiroshi Sakaue6, Kazuhiro Nomura1, Kei Yoshino1, Yuko Nabatame1, Yoshito Itoh7, Kanji Yamaguchi7, Yoshitake Hayashi8, Jun Nakae9, Domenico Accili10, Takehiko Yokomizo11, Susumu Seino12, Masato Kasuga13, Wataru Ogawa14.   

Abstract

Although adipocytes are major targets of insulin, the influence of impaired insulin action in adipocytes on metabolic homeostasis remains unclear. We here show that adipocyte-specific PDK1 (3'-phosphoinositide-dependent kinase 1)-deficient (A-PDK1KO) mice manifest impaired metabolic actions of insulin in adipose tissue and reduction of adipose tissue mass. A-PDK1KO mice developed insulin resistance, glucose intolerance, and hepatic steatosis, and this phenotype was suppressed by additional ablation of FoxO1 specifically in adipocytes (A-PDK1/FoxO1KO mice) without an effect on adipose tissue mass. Neither circulating levels of adiponectin and leptin nor inflammatory markers in adipose tissue differed between A-PDK1KO and A-PDK1/FoxO1KO mice. Lipidomics and microarray analyses revealed that leukotriene B4 (LTB4) levels in plasma and in adipose tissue as well as the expression of 5-lipoxygenase (5-LO) in adipose tissue were increased and restored in A-PDK1KO mice and A-PDK1/FoxO1KO mice, respectively. Genetic deletion of the LTB4 receptor BLT1 as well as pharmacological intervention to 5-LO or BLT1 ameliorated insulin resistance in A-PDK1KO mice. Furthermore, insulin was found to inhibit LTB4 production through down-regulation of 5-LO expression via the PDK1-FoxO1 pathway in isolated adipocytes. Our results indicate that insulin signaling in adipocytes negatively regulates the production of LTB4 via the PDK1-FoxO1 pathway and thereby maintains systemic insulin sensitivity.

Entities:  

Keywords:  5-lipoxygenase; FoxO1; PDK1; insulin resistance; leukotriene B4

Year:  2020        PMID: 32393635      PMCID: PMC7261087          DOI: 10.1073/pnas.1921015117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

Review 1.  The 5 lipoxygenase system in the vasculature: emerging role in health and disease.

Authors:  Etty Osher; Gary Weisinger; Rona Limor; Karen Tordjman; Naftali Stern
Journal:  Mol Cell Endocrinol       Date:  2006-05-02       Impact factor: 4.102

Review 2.  Inflammation and metabolic disorders.

Authors:  Gökhan S Hotamisligil
Journal:  Nature       Date:  2006-12-14       Impact factor: 49.962

3.  Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt.

Authors:  T Kitamura; Y Kitamura; S Kuroda; Y Hino; M Ando; K Kotani; H Konishi; H Matsuzaki; U Kikkawa; W Ogawa; M Kasuga
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

4.  Transcriptional control of adipose lipid handling by IRF4.

Authors:  Jun Eguchi; Xun Wang; Songtao Yu; Erin E Kershaw; Patricia C Chiu; Joanne Dushay; Jennifer L Estall; Ulf Klein; Eleftheria Maratos-Flier; Evan D Rosen
Journal:  Cell Metab       Date:  2011-03-02       Impact factor: 27.287

5.  A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis.

Authors:  T Yokomizo; T Izumi; K Chang; Y Takuwa; T Shimizu
Journal:  Nature       Date:  1997-06-05       Impact factor: 49.962

6.  The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression.

Authors:  J Nakae; T Kitamura; D L Silver; D Accili
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

7.  Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance.

Authors:  Matthias Blüher; M Dodson Michael; Odile D Peroni; Kohjiro Ueki; Nathan Carter; Barbara B Kahn; C Ronald Kahn
Journal:  Dev Cell       Date:  2002-07       Impact factor: 12.270

8.  Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue.

Authors:  Romain A Colas; Masakazu Shinohara; Jesmond Dalli; Nan Chiang; Charles N Serhan
Journal:  Am J Physiol Cell Physiol       Date:  2014-04-02       Impact factor: 4.249

9.  LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes.

Authors:  Pingping Li; Da Young Oh; Gautam Bandyopadhyay; William S Lagakos; Saswata Talukdar; Olivia Osborn; Andrew Johnson; Heekyung Chung; Michael Maris; Jachelle M Ofrecio; Sayaka Taguchi; Min Lu; Jerrold M Olefsky
Journal:  Nat Med       Date:  2015-02-23       Impact factor: 53.440

Review 10.  Lipodystrophy: metabolic insights from a rare disorder.

Authors:  Isabel Huang-Doran; Alison Sleigh; Justin J Rochford; Stephen O'Rahilly; David B Savage
Journal:  J Endocrinol       Date:  2010-09-24       Impact factor: 4.286

View more
  3 in total

1.  Montelukast, an Antagonist of Cysteinyl Leukotriene Signaling, Impairs Burn Wound Healing.

Authors:  Alan V Nguyen; Michelle D Bagood; Marilyn Wang; Sofia E Caryotakis; Glendalyn Smith; Shannon Yee; Haitao Shen; R Rivkah Isseroff; Athena M Soulika
Journal:  Plast Reconstr Surg       Date:  2022-05-10       Impact factor: 5.169

2.  Role of PDK1 in skeletal muscle hypertrophy induced by mechanical load.

Authors:  Naoki Kuramoto; Kazuhiro Nomura; Daisuke Kohno; Tadahiro Kitamura; Gerard Karsenty; Tetsuya Hosooka; Wataru Ogawa
Journal:  Sci Rep       Date:  2021-02-10       Impact factor: 4.379

3.  Kruppel-like factor 15 regulates fuel switching between glucose and fatty acids in brown adipocytes.

Authors:  Yuko Nabatame; Tetsuya Hosooka; Chikako Aoki; Yusei Hosokawa; Makoto Imamori; Yoshikazu Tamori; Yuko Okamatsu-Ogura; Takeshi Yoneshiro; Shingo Kajimura; Masayuki Saito; Wataru Ogawa
Journal:  J Diabetes Investig       Date:  2021-02-15       Impact factor: 4.232

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.